Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer prognosis than young. This may be due to accumulated cellular damage, decreases in adaptive immunity, and chronic inflammation. However, the effects of the aged microenvironment on tumour progression have been largely unexplored. Since dermal fibroblasts can have profound impacts on melanoma progression 1-4 , we examined whether age-related changes in dermal fibroblasts could drive melanoma metastasis and response to targeted therapy. Here we find that aged fibroblasts secrete a Wnt antagonist, sFRP2, which activates a multi-step signalling cascade in melanoma cells that results in a decrease in β-catenin and microphthalmiaassociated transcription factor (MITF), and ultimately the loss of a key redox effector, APE1. Loss of APE1 attenuates the response of melanoma cells to DNA damage induced by reactive oxygen species, rendering the cells more resistant to targeted therapy (vemurafenib). Age-related increases in sFRP2 also augment both angiogenesis and metastasis of melanoma cells. These data provide an integrated view of how fibroblasts in the aged microenvironment contribute to tumour progression, offering new possibilities for the design of therapy for the elderly.
). Proliferation was initially unaffected (Extended Data Fig. 1b ), but aged fibroblasts senesced more rapidly than young fibroblasts (Extended Data Fig. 1c ). Organotypic skin reconstructs were built using two melanoma cell lines (WM35 and WM793) and three young or three aged fibroblast lines, which persisted equally in the skin reconstructs as demonstrated by smooth muscle actin staining (Extended Data Fig. 1d ). Melanoma cell invasion was increased, but proliferation was decreased in reconstructs built with aged fibroblasts (Fig. 1d , e and Extended Data Fig. 1e ). To assess the effects of secreted factors, melanoma cells were exposed to conditioned media from aged or young fibroblasts. Aged fibroblast media decreased melanoma cell proliferation ( Fig. 1f and Extended Data Fig. 1f ), and increased invasion as measured by spheroid and Boyden chamber invasion assays (Fig. 1g, h and Extended Data Fig. 1g ). These data indicate that secreted factors from fibroblasts play critical roles in phenotype switching in melanoma cells.
A key player in phenotype switching is β-catenin, which drives proliferation and inhibits invasion of melanoma cells 14, 15 . An inhibitor of β-catenin, sFRP2, was significantly increased in the secretome of aged fibroblasts (Fig 2a) . In both spheroid and Boyden chamber assays, media from young fibroblasts treated with recombinant sFRP2 (rsFRP2) increased invasion of melanoma cells ( Fig. 2b and Extended Data Fig. 2a ) and media from aged fibroblasts treated with α-sFRP2 inhibited melanoma cell invasion ( Fig. 2c and Extended Data Fig. 2c ). In vivo, sFRP2 was increased in sera from aged mice, and these levels could be nearly attained in young mice by intravenous injection of rsFRP2 ( Fig. 2d ). Increasing serum sFRP2 in young mice increased metastasis of Yumm1.7 to the lung ( Fig. 2e ) and increased angio genesis in subcutaneous tumours ( Fig. 2f and Extended Data Fig. 2c, d) . Tumours in α-sFRP2treated mice showed impaired angiogenesis ( Fig. 2f and Extended Data Fig. 2e, f) . However, α-sFRP2-treated aged mice succumbed to a lethal inflammation (Extended Data Fig. 3) , an outcome previously observed in aged immune-competent mice treated with α-PD1 (ref. 16) .
We next explored the significance of sFRP2 effects on β-catenin expression and activity. Treatment of melanoma cells with rsFRP2 inhibited β-catenin expression (Fig. 2g) , and β-catenin was decreased in aged human skin ( Fig. 2h and Extended Data Fig. 4a ) and in melanoma cells treated with aged fibroblast media (Extended Data Fig. 4b, c ). Yumm1.7 tumours in aged mice exhibited decreased β-catenin and increased sFRP2
Letter reSeArCH ( Fig. 2i ), effects reversed by treatment of aged mice with α-sFRP2 ( Fig. 2j ). Knockdown of β-catenin in young fibroblasts increased their sFRP2 secretion (Fig. 2k) , which reduced β-catenin and increased invasion in melanoma cells ( Fig. 2l and Extended Data Fig. 4d ). These data suggest that sFRP2 present in the aged microenvironment may contribute to melanoma metastasis through suppression of β-catenin in melanoma cells.
The loss of β-catenin permits oxidative stress in haematopoietic stem cells 17 . We hypothesized that the same might occur in melanoma cells, via MITF, which is activated by β-catenin 18 . MITF modulates responses to reactive oxygen species (ROS) by increasing the redox effector APE1 (REF-1) 19 . We predicted that age-induced loss of β-catenin might dysregulate the MITF/APE1 redox pathway. Indeed, melanoma cells exposed to aged fibroblast media have decreased β-catenin, MITF, and APE1 (Fig. 3a) . APE1 expression is lower in aged human skin (Extended Data Fig. 5a ) and in Yumm1.7 tumours in aged mice (Fig. 3b ). Loss of APE1 reduces cellular responses to ROS. ROS activity is increased in aged fibroblasts (Fig. 3c ), partly because aged fibroblasts secrete lower levels of superoxide dismutase 3 (SOD3), and peroxiredoxin 6, which scavenge free radicals (Extended Data Fig. 5b, c) . A marker of oxidative stress, 8-oxo-dG, was increased in aged but not young skin (Extended Data Fig. 5d ) and in tumours in aged mice (Fig. 3d ). Knockdown of APE1 in melanoma cells increases ROS activity, especially upon exposure to aged fibroblast media (Fig. 3e , f and Extended Data Fig. 5e ). We hypothesized that this loss of ability to respond to ROS in an aged environment is partly due to sFRP2 downregulation of APE1. Treating young mice with rsFRP2 increases 8-oxo-dG in Yumm1.7 tumours ( Fig. 3g ), while depleting sFRP2 in aged mice decreases 8-oxo-dG ( Fig. 3g ). Together, these data indicate that sFRP2 increases oxidative stress by inhibiting β-catenin and, ultimately, APE1 in melanoma cells ( Fig. 3h ).
Our model indicates that loss of APE1 owing to age-induced sFRP2 should render melanoma cells sensitive to DNA damage (Extended Data Fig. 6a ). Accordingly, microarray analysis reveals an increased DNA damage response signature in melanoma cells exposed to aged fibroblasts (Extended Data Fig. 6b , c). The DNA damage markers γH2AX and 53BP1 are increased in melanoma cells grown in aged mice ( Fig. 4a ), or exposed to aged fibroblast media ( Fig. 4b ) or in skin reconstructs built with aged fibroblasts (Extended Data Fig. 7a, b ). Melanoma cells exposed to aged media also had increased levels of DNA damage ( Fig. 4c and Extended Data Fig. 7c ). Pre-treating aged fibroblasts with the anti-oxidant N-acetyl-l-cysteine (NAC) decreased ROS (Extended Data Fig. 7d ) and, subsequently, γH2AX in melanoma cells ( Fig. 4d ). Conversely, knockdown of the anti-oxidant SOD3 in young fibroblasts increased γH2AX in melanoma cells ( Fig. 4e and Extended Data Fig. 7e ), suggesting that age-induced DNA damage could be reversed by inhibiting ROS activity.
We next queried the contribution of the sFRP2 → APE1 signalling axis to ROS-induced DNA damage. Loss of APE1 increases γH2AX ( Fig. 4f ). In melanoma cells, γH2AX also increases with treatment of rsFRP2, and decreases in cells where sFRP2 is deleted ( Fig. 4g and Extended Data Fig. 7f , g). In vivo, 53BP1 increases in Yumm1.7 tumours in young mice treated with rsFRP2, and decreases in aged mice treated with α-sFRP2 ( Fig. 4h ). Aged melanoma patients (over 55 years) had significantly higher serum levels of sFRP2 (P = 0.0084) than young patients (under 40 years) ( Fig. 4i ). The key players in the pathway outlined in Fig. 3h were altered in aged melanoma patients: increased sFRP2 (in both fibroblasts and melanoma cells), decreased β-catenin, MITF, and APE1, and increased 8-oxo-dG and 53BP1 ( Fig. 4j and Extended Data Fig. 8 ). These data confirmed our observations both from human cell line and from mouse data.
Increases in ROS 20, 21 and decreases in β-catenin 9,22 and MITF 23 have been associated with increased resistance to BRAF inhibitors. Accordingly, spheroids treated with young medium were more sensitive to PLX4720 (vemurafenib) than those exposed to aged medium (Extended Data Fig. 9a ). In vivo, Yumm1.7 tumours in young mice responded to PLX4720 more robustly than tumours in aged mice ( Fig. 5a, b ). Melanoma cells first exposed to media from young fibroblasts treated with H 2 O 2 (to increase ROS) developed resistance to PLX4720 (Fig. 5c ). However, when we first exposed melanoma cells to media from aged fibroblasts pre-treated with NAC, the melanoma cells died, whether treated with NAC alone or with NAC + PLX4720 ( Fig. 5d, e ). This indicated that vemurafenib-resistant cells in an aged microenvironment might be uniquely sensitive to anti-oxidants. .7_mCherry cells subcutaneously injected in young (8 weeks, n = 10) and aged (52 weeks, n = 10) C57/BL6 mice. (Analysis of variance (ANOVA) P < 0.0001; multiple comparison's test using Bonferroni correction, P < 0.0001 after day 19.) b, CD31 expression from a (original magnification ×200). Graph indicates percentage of mice with extensive angiogenesis (multiple CD31 + vessels per field). c, mCherry staining in mouse lungs (positive cells circled in blue; original magnification ×400). d, WM35 melanoma cells in skin reconstructs built with young or aged fibroblasts (n = 3, original magnification ×150). Invasion was quantified using ImageJ (ANOVA P = 0.0006). e, Ki67 staining from d (original magnification ×400). f, Proliferation of WM35 melanoma cells in conditioned media from young or aged fibroblasts (n = 4 fibroblasts per group; ANOVA, P = 0.004; Holm-Šídák correction (day 6 (P = 0.002), day 8 (P = 0.034)). g, Invasion of melanoma spheroids exposed to aged or young conditioned media (n = 2 fibroblasts per group, original magnification ×40, two-tailed unpaired t-test, P = 0.041). h, Boyden chamber invasion of FS5 melanoma cells treated with young versus aged fibroblast media (original magnification ×150, two-tailed unpaired t-test, P = 0.043). Data represented as mean ± s.d. (a, d, g, h). 
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This finding is especially exciting in light of recent data that indicate that anti-oxidants are effective in treating KRAS and BRAF mutant colon cancers 24 .
Phenotype switching resulting in the loss of β-catenin has also been shown to contribute to resistance to vemurafenib 9, 22 . β-Catenin expression is elevated in sensitive versus resistant cell lines (Extended Data Fig. 9b ). Further, patients with clinical response to vemurafenib (over 30% tumour reduction as measured by RECIST) had higher levels of β-catenin than those with muted response ( Fig. 5f , g). Yumm1.7 cells are sensitive to PLX4720, and knocking down Ctnnb1 in these cells significantly increased their resistance to PLX4720 (Extended Data Fig. 9c ). To determine whether sFRP2 alters the response of melanoma cells to vemurafenib, rsFRP2 was administered intravenously to tumour-bearing young mice, before and during PLX4720 exposure. β-Catenin was decreased in the skin of sFRP2treated mice (Extended Data Fig. 9d ), and treated mice rapidly developed resistance to PLX4720 ( Fig. 5h ). Depletion of sFRP2 in aged mice began to re-sensitize tumours to PLX4720 ( Fig. 5i and Extended Data Fig. 9e ), but a firm conclusion cannot be drawn from these data because of the premature death of the mice as described earlier. , treated with rsFRP2 (200 ng ml −1 , 48 h, two-tailed unpaired t-test, P = 0.046). c, Melanoma spheroids treated with media from aged fibroblasts pre-treated with either IgG2aκ, or α-sFRP2 monoclonal antibody (15 μg ml −1 , 48 h, original magnification ×40, two-tailed unpaired t-test, P = 0.023). d, sFRP2 in mouse serum (n = 10 per group): young, aged, and young + 200 ng ml −1 rsFRP2. ANOVA (P = 0.015), two-tailed unpaired t-test (PBS versus rsFRP2 (P = 0.045), young versus aged mice (P = 0.007)). e, One million mCherry-labelled Yumm1.7 cells were injected intravenously into PBS-or rsFRP2-(200 ng ml −1 ) treated young mice (6-8 weeks, n = 10 per group). Graph indicates percentage of positive lungs recorded as IVIS fluorescence intensity where highest intensity is 3+ (green; that is, multiple metastatic foci) and 0 is lowest intensity (black; that is, no metastases). f, Yumm1.7 tumours in young mice (6-8 weeks, n = 10 per group) treated with either PBS or rsFRP2 (200 ng ml −1 ) or in aged mice (52 weeks, n = 5 per group) treated with either control IgG2aκ, or α-sFRP2 monoclonal antibody (1 mg kg −1 ) were assessed for CD31 (original magnification ×400). g, Western analysis of non-phosphorylated (active) β-catenin in melanoma cells treated with rsFRP2 for 48 h. h, β-Catenin expression in young and aged human skin (<35 years, n = 12; >55 years, n = 7). Slides were scored for positivity (3, highest; 0, lowest) (original magnification ×400, unpaired t-test using rank-sum (P = 0.019)). i, sFRP2 and β-catenin in Yumm1.7 tumours in young and aged mice (original magnification ×600). j, Aged tumour-bearing mice (>52 weeks, n = 5 per group) treated with α-sFRP2 monoclonal antibody (1 mg kg −1 ). Tumours were stained for β-catenin (original magnification ×400). k, sFRP2 ELISA in shCTNNB1 versus shCTRL fibroblast media. Two-tailed unpaired t-test (2003-071-032 (P = 0.015), TP113 (P = 0.008)). l, Invasion of melanoma spheroids treated with TP113 shCTNNB1 conditioned media for 48 h (original magnification ×40). Data represented as mean ± s.d. and MITF in melanoma cells exposed to aged or young fibroblast media. b, APE1 in Yumm1.7 tumours in aged and young mice, percentage positive tumours is quantified (original magnification ×400). c, ROS levels in multiple young and aged fibroblasts (two-tailed unpaired t-test, P = 0.022). d, Percentage positive 8-oxo-dG Yumm1.7 tumours implanted in aged and young mice (original magnification ×400). e, Western analysis of WM35 melanoma cells after APE1 knockdown. f, ROS levels in shAPE1 melanoma cells in absence (two-tailed t-test, P = 0.012), and presence (two-tailed t-test, P = 0.008) of conditioned media from aged fibroblasts. g, Levels of 8-oxo-dG assessed in tumours from young mice treated with either PBS or rsFRP2 and aged mice treated with either IgG2aκ or α-sFRP2 (original magnification ×400). h, Schematic of sFRP2 effects in melanoma cells exposed to aged or young fibroblasts. Data represented as mean ± s.d. (c, f).
Since these data suggested that response to BRAF inhibitors might be attenuated in aged patients, we compared the age of patients (n = 79) at start of treatment with percentage tumour reduction (RECIST) after treatment with vemurafenib. Using age categories of under 35 and over 55, we saw a shift from a 41% (mean) response by RECIST in young patients to 25% (mean) response in patients over 55. Numbers of young patients were too low to achieve statistical significance. We therefore refocused our efforts on identifying an age cutoff where a statistically , embedded in collagen and treated with young media containing 1 μM PLX4720 (ANOVA, P < 0.0001). Area was measured as a gauge of spheroid health. d, WM35 spheroids were embedded in collagen and treated with aged media containing 1 μM PLX4720 and/or 20 mM NAC. Invasion was measured after 48 h (representative images, original magnification ×40, one-way ANOVA, P = 0.02). 20 mM NAC (unpaired t-test, P = 0.03) and 1 μM PLX4720 (two-tailed unpaired t-test, P = 0.006) compared with control. e, Live-dead staining of spheroids from d (ANOVA, P < 0.0001; Holm-Šídák multiple comparisons test indicated (P < 0.0001) after pre-treatment with 20 mM NAC in presence of either control or 1 μM PLX4720). f, β-Catenin staining of biopsies (original magnification ×200) from patients undergoing vemurafenib treatment (percentage indicates percentage RECIST response). g, Tabulation of patient samples correlating H-score (intensity of stain per field of cells) to RECIST response (two-tailed paired t-test, P = 0.035); 30% is considered a responder by RECIST criteria. h, Young mice (n = 10 per group) with Yumm1.7 tumours were treated with rsFRP2 (200 ng ml −1 ) twice a week. PLX4720 (417 mg kg −1 ) was administered once the tumour reached 500 mm 3 . rsFRP2-treated (black line) versus control (red line) young mice (ANOVA, P = 0.009; Holm-Šídák corrected multiple comparisons, P < 0.05 after day 12, mean ± s.e.m.). i, Yumm1.7 tumours were injected in aged mice (52 weeks, n = 5 per group) pre-treated with α-sFRP2 antibody (1 mg kg −1 , once weekly). Mice were administered control or 417 mg kg −1 PLX4720laced chow. Tumour volume at day 25 is shown (unpaired t-test with Welch's correction, P = 0.048). j, RECIST response in patients younger than 65 years versus those older than 65 years. Two-sample Wilcoxon rank-sum (Mann-Whitney) test indicated statistical significance (P = 0.016). Data represented as mean ± s.d. (a-c, e, i, j). Letter reSeArCH significant difference could be observed. We observed a striking separation (P = 0.016) between patients under 65 years and over 65 years (~25.6% reduction in tumour burden in aged compared with ~47% in the young, Fig. 5j ). The continuous relationship between response and age was highly significant (Spearman's correlation coefficient of r = 0.243, P = 0.03) (Extended Data Fig. 9f ). However, in this small sample set, the relationship between patient age, sFRP2, and RECIST was not significant. Together, these data suggest that sFRP2-induced β-catenin loss not only promotes invasion, but also renders melanoma cells more sensitive to oxidative stress. New data from ref. 24 show that therapy-refractory, BRAF mutant cells are sensitive to antioxidants, specifically vitamin C. Our data support these observations, and suggest that aged patients may uniquely benefit from anti-oxidant therapy.
In our experiments, genetically identical cells had a very different outcome in terms of metastasis and therapy response when placed in an aged microenvironment. In the skin, benign melanocytic lesions (naevi) bear mutational changes that do not result in tumorigenesis, until cells accumulate further changes during ageing. These changes may be genetic, such as loss of p16, but they may also be epigenetic, and age-related epigenetic changes also contribute to tumorigenesis [25] [26] [27] . What drives the initiation of these epigenetic changes is not well understood, and it is possible that the aged secretome contributes to this process. While overall results were consistent among different fibroblasts of similar ages, we did observe some phenotypic differences. These may be attributable to factors such as tanning, as, indeed, the exposure of melanoma cells to ultraviolet irradiation not only drives tumour promotion 28 but also metastasis 29 . Our data suggest that, as the general population ages, new efforts must be made to understand and treat cancer in an age-appropriate manner.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Cell culture. FS5, FS4, FS13, FS14, M93-047, UACC-903, and UACC-1273 cells were maintained in RPMI (Invitrogen), supplemented with 10% FBS, 100 units per millilitre penicillin and streptomycin, and 4 mM l-glutamine. WM35, WM793, WM164, WM1799, and 1205 LU cells were maintained in MCDB153 (Sigma)/L-15 (Cellgro) (4:1 ratio) supplemented with 2% FBS and 1.6 mM CaCl 2 (tumour growth media). WM983b and WM3918 cells were maintained in DMEM (Invitrogen), supplemented with 5% FBS, 100 units per millilitre penicillin and streptomycin, and 4 mM l-glutamine. YUMM1.7 cells were maintained in DMEM F-12 (HEPES/ glutamine) supplemented with 10% FBS, 1% NEAA, and 100 units per millilitre penicillin and streptomycin. Fibroblasts were maintained in DMEM, supplemented with 10% FBS, 100 units per millilitre penicillin and streptomycin, and 4 mM l-glutamine. Keratinocytes were maintained in keratinocyte SFM supplemented with human recombinant Epidermal Growth Factor 1-53 (EGF 1-53) and Bovine Pituitary Extract (BPE) (Invitrogen). Cell lines were cultured at 37 °C in 5% CO 2 and the medium was replaced as required. Cell stocks were fingerprinted using an AmpFLSTR Identifiler PCR Amplification Kit from Life Technologies at The Wistar Institute Genomics Facility. Although it is desirable to compare the profile with the tissue or patient of origin, our cell lines were established over the course of 40 years, long before acquisition of normal control DNA was routinely performed. However, each short tandem repeat profile is compared with our internal database of over 200 melanoma cell lines, as well as control lines, such as HeLa and 293 T. Short tandem repeat profiles are available upon request. Cell culture supernatants were tested for mycoplasma using a Lonza MycoAlert assay at the University of Pennsylvania Cell Center Services. Organotypic three-dimensional skin reconstructs. Organotypic three-dimensional skin reconstructs were generated as previously described 30 . In each insert, 6.4 × 10 4 fibroblasts were plated on top of the acellular layer (BD 355467 and Falcon 353092) and incubated for 45 min at 37 °C in a 5% CO 2 tissue culture incubator. DMEM containing 10% FBS was added to each well of the tissue culture trays and incubated for 4 days. Reconstructs were then incubated for 1 h at 37 °C in HBSS containing 1% dialysed FBS (wash media). Washing media were removed and replaced with reconstruct media I. Keratinocytes (4.17 × 10 5 ) and melanoma cells (8.3 × 10 4 ) were added to the inside of each insert. Media were changed every other day until day 18 when reconstructs were harvested, fixed in 10% formalin, paraffin embedded, sectioned, and stained. Quantification of the invasion was performed using ImageJ software (available at http://imagej.nih.gov/ij/; developed by W. Rasband). Three-dimensional spheroid assays. Tissue-culture-treated 96-well plates were coated with 50 μl 1.5% Difco Agar Noble (Becton Dickinson). Melanoma cells were seeded at 5 × 10 3 cells per well and allowed to form spheroids over 72 h. Spheroids were harvested and embedded as previously described using collagen type I (GIBCO, A1048301). For spheroids incubated with fibroblast conditioned media, fibroblasts were seeded onto 75 cm 2 flasks at 7 × 10 5 to 9 × 10 5 per flask depending on growth rate. Sixteen hours later, media were replaced and incubated for 72 h. Media from young fibroblasts were combined and media from aged fibroblasts were combined. These conditioned media were added to the top of the collagen plug containing the spheroids. Quantitation of invasive surface area was performed using NIS Elements Advanced Research software. Live-dead staining. Spheroids were generated and embedded as described above. Spheroids were stained using a LIVE/DEAD Viability/Cytotoxicity Kit (L3224, Invitrogen). Briefly, spheroids were washed with PBS and stained with calcein AM/ Ethidium homodimer-1. The dyes were diluted in PBS and 300 μl of the solution was added on the spheroid wells for 1 h at 37 °C. The spheroids were washed in PBS and imaged using a Nikon TE2000 Inverted Microscope. Quantitation of fluorescence intensity was performed using NIS Elements Advanced Research software. Boyden chamber invasion assays. Matrigel (BD Biosciences, 354234) was diluted in PBS (1:3,000 dilution). One hundred and fifty microlitres of this mixture was pipetted into each insert of the invasion assay plate (Corning, 3422). The plate was incubated at 37 °C for 2 h and then dried at room temperature (25 °C) overnight under sterile conditions. Melanoma cells were pre-treated for 48 h in six-well plates. After 48 h, the cells were harvested and 1.5 × 10 5 cells were added to each transwell. High concentration serum media (RPMI with 20% FCS, tumour growth media with 10% FCS) were added to the outside (bottom) of the well. The plates were incubated at 37 °C until cells had migrated to the bottom of the well. The migrated cells were fixed in 95% ice-cold methanol and stained with crystal violet (0.5%) for 10 min. The stain was washed and the wells were left to dry. Cells were imaged and quantified using ImageJ software. Cellular proliferation assays. In a 24-well plate, 5,000 cells in triplicate were plated per day of measurement. Every 2-3 days, cells were counted using a haemocytometer and the total cell number in the well was recorded and plotted on GraphPad Prism. Immunofluorescence. Cells were seeded onto glass cover slips at 1 × 10 4 to 4 × 10 4 cells per well, and incubated overnight. After treatment, cells were fixed using 95% methanol. Primary antibodies were diluted as stated above in blocking buffer and incubated overnight at 4 °C. Cells were washed in PBS and incubated with the appropriate secondary antibody (1:2,000, Invitrogen) for 1 h at room temperature. Cells were then washed in PBS and mounted in Prolong Gold anti-fade reagent containing DAPI (Invitrogen). Images were captured on a Leica TCS SP5 II scanning laser confocal system. Immunohistochemistry. All antibodies are described in the Supplementary Information. Patient samples were collected under IRB exemption approval for protocol EX21205258-1. Paraffin embedded sections were rehydrated through a xylene and alcohol series, rinsed in H 2 O and washed in PBS. Antigen retrieval was performed using target retrieval buffer (Vector Labs) and steamed for 20 min. Samples were then blocked in a peroxidase blocking buffer (Thermo Scientific) for 15 min, followed by Protein block (Thermo Scientific) for 5 min, and incubated in appropriate primary antibody diluted in antibody diluent (S0809, Dako) at 4 °C overnight in a humidified chamber. For mouse samples to be incubated with anti-mouse antibody, samples were blocked for 1 h in Mouse on Mouse (M.O.M.) Blocking Reagent (MKB-2213, Vector Labs). After washing in PBS, samples were incubated in biotinylated anti-rabbit or polyvalent secondary antibody (Thermo Scientific) followed by streptavidin-HRP solution at room temperature for 20 min. Samples were then washed in PBS and incubated in 3-amino-9-ethyl-l-carboazole (AEC) chromogen and counterstained with Mayer's haematoxylin for 1 min, rinsed in cold H 2 O, and mounted in Aquamount. Western blotting. Total protein lysate (50-65 μg) was run on a 4-12% NuPAGE Bis Tris gel (Invitrogen). Proteins were then transferred onto PVDF membrane using an iBlot system, and blocked in 5% milk/TBST for 1 h. All primary antibodies were diluted in 5% milk/TBST and incubated over night at 4 °C. The membranes were washed in TBST and probed with the corresponding HRP-conjugated secondary antibody (0.2-0.02 μg ml −1 of anti-mouse, streptavidin, or anti-rabbit). Proteins were visualized using ECL prime (Amersham), or Luminata Crescendo (Millipore). Lentiviral infection. All clones used are described in the Supplementary Information. All short hairpin RNA (shRNA) was obtained from the TRC shRNA library available through the Molecular Screening Facility at The Wistar Institute. Lentiviral production was performed as described in the protocol developed by the TRC library (Broad Institute). Briefly, 293 T cells were co-transfected with shRNA vector and lentiviral packaging plasmids (pCMV-dR8.74psPAX2, pMD2.G). The supernatant containing virus was harvested at 36 and 60 h, combined and filtered through a 0.45 μm filter. For transduction, the cells were layered overnight with lentivirus containing 8 μg ml −1 polybrene. The cells were allowed to recover for 24 h and then selected using 1 μg ml −1 puromycin. MTS assays. Cells (1.5 × 10 3 per well) were plated in a 96-well plate and treated with PLX4720. After 48 h, cells were incubated with MTS dye (20 μl per well) for 2 h. Absorbance was determined at 490 nm using an EL800 microplate reader (BioTek). The percentage cell proliferation was calculated by converting the experimental absorbance to percentage of control and plotted versus drug concentration. The values were then analysed using a nonlinear dose-response analysis in GraphPad Prism. Illumina oligonucleotide microarray. Transcriptional profiling was determined using Illumina Sentrix BeadChips. Total RNA was used to generate biotinlabelled cRNA using the Illumina TotalPrep RNA Amplification Kit. In short, 0.5 μg of total RNA was first converted into single-stranded complementary DNA (cDNA) with reverse transcriptase using an oligo-dT primer containing the T7 RNA polymerase promoter site and then copied to produce double-stranded cDNA molecules. The double-stranded cDNA was cleaned and concentrated with the supplied columns and used in an overnight in vitro transcription reaction where single-stranded RNA (cRNA) was generated incorporating biotin-16-UTP. A total of 0.75 μg of biotin-labelled cRNA was hybridized at 58 °C for 16 h to Illumina's Sentrix Human HT-12 v3 Expression BeadChips (Illumina). Each BeadChip has around 48,000 transcripts with approximately 15-fold redundancy. The arrays were washed, blocked, and the labelled cRNA was detected by staining with streptavidin-Cy3. Hybridized arrays were scanned using an Illumina BeadStation 500X Genetic Analysis Systems scanner and the image data extracted using the Illumina GenomeStudio software, version 1.1.1). Data are available in the GEO database (accession number GSE57445). Microarray analysis. Microarray expression data were quantile normalized and probes that showed low expression levels (detection P value > 0.05) across all samples were removed from the analysis. Expression values for each cell line were tested separately in multiple linear regression model with fibroblast age and experiment batches as predictor variables. Matlab version 8.0 'regress' function was used to calculated P values for each probe for association with fibroblast age.
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False discovery rate was estimated using Benjamini-Hochberg procedure; only probes that showed a false discovery rate < 5% in all three cell lines were considered significant. Heat map was plotted using average expression values for three groups of age (young, middle, and aged) normalized to aged group (100%). In vivo tail vein metastases assay. All animal experiments were approved by the Institutional Animal Care and Use Committee (112503Y_0) and were performed in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. From preliminary studies, we observed significant differences (more than 1.8 standard deviations, a very large effect size) in some of the outcomes between young and aged groups. As few as five samples in each group in this study afforded 80% power at a two-sided α of 0.05 to detect a difference of about 1.8 standard deviations in a continuous outcome between young and aged groups, but we increased the sample size slightly to account for potential loss of mice due to health issues associated with ageing. Male C57BL6 mice at 6-8 weeks (young) and 52 weeks (aged) were purchased from Taconic. YUMM 1.7 (1 × 10 6 cells per 100 μl PBS) or B16F10 (2.5 × 10 5 per 100 μl PBS) were injected into the tail vein of C57BL6 mice. Alternatively, Yumm1.7 cells were overexpressed with mCherry plasmid (pLU-EF1-MCS-mCherry) using lentivirus. The cells were sorted for mCherry and 1 × 10 6 cells per 100 μl PBS were injected into tail vein of young C57BL6 mice. After 4 weeks, the mice were euthanized, lungs were harvested, and metastases counted. Lungs were fixed in paraffin and stained with haematoxylin and eosin. Alternatively, lungs were harvested and imaged for presence of metastatic melanoma cells using a Perkin-Elmer IVIS 200 whole body imager. For experiments requiring rsFRP2, mouse rsFRP2 (1169-FR-025/CF, R&D) was diluted in 50 μl PBS and injected at a concentration of 200 ng per mouse twice a week. The levels of sFRP2 were monitored by submandibular blood withdrawal every 2 weeks. In vivo PLX4720 assay. All animal experiments were approved by the Institutional Animal Care and Use Committee (112503X_0) and were performed in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. From preliminary studies, we observed significant differences (more than 1.8 standard deviations, a very large effect size) in some of the outcomes between young and aged groups. As few as five samples in each group in this study afforded 80% power at a two-sided α of 0.05 to detect a difference of about 1.8 standard deviations in a continuous outcome between young and aged groups, but we increased the sample size slightly to account for potential loss of mice due to health issues associated with ageing. YUMM1.7 (2.5 × 10 5 cells) were suspended in Matrigel (500 μg ml−1) and injected subcutaneously into young (6 week) and aged (52 week) C57/BL6 mice (Taconic). When resulting tumours reached 200 mm3, mice were fed either AIN-76A chow or AIN-76A chow containing 417 mg kg −1 PLX4720. Tumour sizes were measured every 3-4 days using digital callipers, and tumour volumes were calculated using the following formula: volume = 0.5 × (length × width 2 ). Time-to-event (survival) was determined by a fivefold increase in baseline volume (~1,000 mm 3 ) and was limited by the development of skin necrosis. Upon the occurrence of necrosis, mice were euthanized. For subsequent experiments involving sFRP2 manipulation, Yumm1.7 cells overexpressing mCherry were used. One million cells were suspended in PBS and subcutaneously injected into either 6-week-old or 52-week-old male C57/BL6 mice (Taconic). For treatment with rsFRP2, the mice were injected with recombinant protein (200 ng ml −1 ) through the tail vein every 2 days as described above. For the experiments performed with sFRP2 blocking antibody (clone 80.8.6, MABC539, EMD Millipore), the mice were treated with 1 mg kg −1 antibody (either sFRP2 or isotype control, Biolegend, 400264) once a week through tail vein injections. Comet assay. WM35 and FS5 melanoma cells were seeded in 12-well plates and treated with conditioned media for 48 h. The cells were harvested in ice-cold PBS. The comet assay was performed using CometSlides (Trevigen). Briefly, 75 μl of a 2 × 10 5 cell suspension was mixed with 500 μl 1% low melting point agarose. Fifty microlitres of cell/agarose mixture was dropped into the wells and allowed to solidify. Slides were incubated in lysis buffer (1.2 M NaCl, 100 nM EDTA, 0.1% Sarkosyl, pH 10.0) for 1 h at 4 °C. Slides were then electrophoresed at 25 V for 12 min in alkaline buffer (0.03 M NaOH, 2 mM EDTA, pH 8.0). After fixation in 70% ethanol, comets were visualized by staining with SYBR Green (Fisher). The extent of DNA damage was measured as the artificial Olive Moment using Cometscore software downloaded from http://www.tritekcorp.com. ROS activation assay. Five thousand melanoma cells were seeded in a 96-well plate in triplicate. The cells were then treated with conditioned media from young and aged fibroblasts as well as DMEM as control. Hydrogen peroxide was added at 1 mM as control. After 72 h, ROS were measured using a Cell Meter Fluorimetric Intracellular Total ROS Activity Assay Kit (22901, AAT Bioquest) according to the manufacturer's protocol. The plates were measured using a PerkinElmer EnVision Xcite Multilabel plate reader using the filters for excitation/emission (Ex/Em) = 520/605 nm. Alternatively, samples were imaged using PerkinElmer Operetta and the fluorescent signal was quantified with Harmony 3.0 software. The cell number was determined by Hoescht staining (Hoechst 33342, Invitrogen) and used to normalize the total fluorescence obtained from ROS staining. Topflash assay. Topflash vectors were obtained from Addgene (M51 Super 8x FOPFlash/TOPFlash mutant, 12457; M50 Super 8x TOPFlash, 12456). WM35 cells were plated to achieve 70% confluency in six-well plates. Cells were co-transfected with pTK-RLuc (Green Renilla Luciferase) along with either Topflash or Fopflash vectors. After 5 h of transfection, cells were treated as required. After 48 h, cells were harvested and luciferase activity was measured using a Dual-Luciferase Reporter (DLR) Assay System (Promega, E1910). The firefly luciferase signal from each well was normalized to its Renilla luciferase signal. Topflash/fopflash signal was determined from each treatment and graphed using Graphpad/Prism. Treatment with NAC. NAC was obtained from Sigma (A9165) and dissolved in sterile distilled H 2 O (stock 1 M). Cells were treated for 48 h and analysed. After optimization, 10 mM final concentration was used for subsequent experiments. Cell fractionation. Melanoma cells were seeded into T25 flasks and incubated for 72 h with 6.5 ml conditioned fibroblast media prepared as described above. Cells were then washed in PBS, harvested with TrypLE Express and fractionated using the cellular fractionation kit (NE-PER, Fisher) as per the manufacturer's protocol. Cell lysates were then separated on an SDS-polyacrylamide gel electrophoresis gel and visualized using standard western blotting procedures. ELISA. Nunc MaxiSorp ELISA plates (ebiosciences) were coated with 50 μl of 3 μg ml −1 sFRP2 (ab137560, Abcam) overnight at 4 °C. Plates were washed in PBS containing 0.1% Tween and blocked in ELISA diluent (00-4202-56, eBioscience) for 2 h. Serum was diluted 1:100 before addition to the plates and incubated overnight at 4 °C. The next day, the plates were washed in PBS containing 0.1% Tween20 and incubated with detection antibody (MAB6838, R&D Systems) for 1 h at room temperature. Plates were washed and incubated with secondary antibody for 1 h. After washing, 100 μl TMB (00-4201-56, eBioscience) was added to the plates and incubated for 15 min The reaction was stopped using 50 μl of 2 N H 2 SO 4 and absorbance was measured at 450 nm. β-Galactosidase staining. Fibroblasts were plated into 12-well dishes, incubated for 48 h, washed with PBS, and fixed in 2% formaldehyde/0.2% glutaraldehyde. Cells were then incubated in staining solution (150 mM NaCl, Sigma), 2 mM MgCl 2 (Sigma), 5 mM K 3 Fe(CN) 6 (Millipore), 5 mM K 4 Fe(CN) 6 (Millipore), 40 mM Na 2 PO 4 (Sigma) pH 5.5, 20 mg ml −1 X-gal (Applichem, Darmstadt, Germany) at 37 °C overnight. Stain was removed and cells were stored in 70% glycerol before being imaged. Quantitative PCR. All primers are listed in the Supplementary Information. Mouse tissue was snap frozen in liquid nitrogen immediately after harvesting. Ten milligrams of the lung tissue was homogenized and RNA was extracted using Trizol (Invitrogen) and RNeasy Mini kit (Qiagen) as described previously. One microgram of RNA was used to prepare cDNA using iscript DNA synthesis kit (1708891, Bio-Rad). cDNA was diluted 1:5 before use in further reactions. Each 20 μl well reaction comprised 10 μl Power SYBR Green Master mix (4367659, Invitrogen), 1 μl primer mix (Final concentration 0.5 μM), and 1 μl cDNA. Standard curves were generated for all primers and each set of primers was normalized to an 18 s primer pair. Statistical analysis. For in vitro studies, a Student's t-test or Wilcoxon rank-sum (Mann-Whitney) test was performed for two-group comparisons. Estimate of variance was performed and parameters for the t-test were adjusted accordingly using Welch's correction. An ANOVA or Kruskal-Wallis test with post-hoc Bonferroni's or Holm-Šídák's adjusted P values was used for multiple comparisons. For doseresponse analysis, Spearman's correlation was calculated. For in vivo studies, the indicated sample size for each experiment was designed to have 80% power at a two-sided α of 0.05 to detect a difference of large effect size of about 1.25 between two groups on a continuous measurement. The fold change in tumour volume at each time point after treatment relative to baseline was calculated and then the fold change in treatment group relative to the age-matched control group was used with a mixed-effect model to evaluate the treatment effect between age groups. Stata 12.0 (StataCorp) was used for data analysis for in vivo studies and human samples. For other experiments, Graphpad/Prism6 was used for plotting graphs and statistical analysis. Significance was designated as follows: *P < 0.05; **P < 0.01; ***P < 0.001. Extended statistical analyses for patient data are provided in the Supplementary Information. 
Extended Data Figure 2 | sFRP2 promotes invasion and angiogenesis. a, Conditioned media from young fibroblasts treated with either control (PBS) or rsFRP2 (200 ng ml −1 ) were used to pre-treat WM793 melanoma cells for 48 h. Invasion was assayed using a Boyden chamber assay over 24-72 h. Two-tailed unpaired t-test was performed (P = 0.033). b, Conditioned media from aged fibroblasts treated with sFRP2 blocking antibody (15 μg ml −1 ) for 72 h were used to pre-treat WM793 melanoma cells for 48 h. The invasion of melanoma cells was assessed in a Boyden chamber assay for 24-72 h. Two-tailed unpaired t-test was performed (P = 0.035). c, d, Young mice (8 weeks, 10 per group) were injected subcutaneously with Yumm1.7 cells. After palpable tumour appeared, mice were treated with rsFRP2 (200 ng ml −1 ) for 30 days and examined for angiogenesis using CD31 staining. Representative images, original magnification ×400. e, f, Aged mice (52 weeks, n = 5 per group) were injected subcutaneously with Yumm1.7 cells and treated with either control (e) IgG2aκ or (f) sFRP2 blocking antibody (1 mg kg −1 ) for 3 weeks. Tumours were examined for angiogenesis by CD31 staining. Representative images, original magnification ×400. Data are represented as mean ± s.d. for each graph (a, b). 
Extended Data Figure 6 | Gene expression analysis of melanoma cells exposed to aged fibroblasts reveals increases in DNA damage. a, γH2AX expression was analysed in melanoma cells exposed to H 2 O 2 using immunofluorescence. b, Microarray analysis of the gene expression profiles of melanoma cells exposed to young/middle and aged fibroblasts identified 63 genes commonly increased in three melanoma cell lines cultured with aged versus young fibroblasts. c, Thirty-three genes involved in DNA damage response were significantly altered because of effects of ageing microenvironment in three different melanoma cell lines. Colour scale indicates expression levels relative to aged group. Y, young; M, middle; A, aged.
In Fig. 5a of this Letter, the labels PBS and PLX4720 were inadvertently reversed. The corrected Fig. 5a is shown in Fig. 1 of this Corrigendum. 
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